Patents by Inventor Mark Matteucci

Mark Matteucci has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Phosphoramidate Alkylator Prodrugs
    Publication number: 20140170240
    Abstract: Phosphoramidate alkylator prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
    Type: Application
    Filed: December 10, 2013
    Publication date: June 19, 2014
    Applicant: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Jian-Xin Duan, Hailong Jiao
  • UNIT DOSE FORM FOR ORAL ADMINISTRATION
    Publication number: 20140072624
    Abstract: Formulations and unit dose forms of TH-302 and other hypoxia activated prodrugs suitable for oral administration are useful for treating cancer.
    Type: Application
    Filed: April 13, 2012
    Publication date: March 13, 2014
    Applicant: THRESHOLD PHARMACEUTICALS, INC.
    Inventors: Donald Jung, Mark Matteucci, Stewart Kroll
  • Phosphoramidate alkylator prodrugs
    Patent number: 8664204
    Abstract: Phosphoramidate alkylator prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
    Type: Grant
    Filed: July 12, 2013
    Date of Patent: March 4, 2014
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Jian-Xin Duan, Hailong Jiao
  • PHOSPHORAMIDATE ALKYLATOR PRODRUGS
    Publication number: 20130303778
    Abstract: Phosphoramidate alkylator prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
    Type: Application
    Filed: July 12, 2013
    Publication date: November 14, 2013
    Inventors: Mark Matteucci, Jian-Xin Duan, Hailong Jiao, Jacob Kaizerman
  • Camptothecin derivatives
    Patent number: 8575188
    Abstract: Various 14-nitro, 14-amino, and 14-substituted amino camptothecin derivatives are useful in the treatment of cancer and other hyperproliferative diseases. 14-Nitro camptothecin derivatives are conveniently prepared by reacting a camptothecin derivative with fuming nitric acid, optionally employing acetic anhydride as a solvent.
    Type: Grant
    Filed: June 16, 2010
    Date of Patent: November 5, 2013
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventors: Xiaohong Cai, Jian-Xin Duan, Mark Matteucci, Yeyu Cao, Hailong Jiao
  • Phosphoramidate alkylator prodrugs for the treatment of cancer
    Patent number: 8552048
    Abstract: Compositions containing, and, methods administering, TH302, are useful in treatment of cancer and other hyper-proliferative diseases.
    Type: Grant
    Filed: December 21, 2007
    Date of Patent: October 8, 2013
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventors: Steve Ammons, Jian-Xin Duan, Donald Jung, Mark Matteucci
  • Phosphoramidate alkylator prodrugs
    Patent number: 8507464
    Abstract: Phosphoramidate alkylator prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
    Type: Grant
    Filed: June 17, 2011
    Date of Patent: August 13, 2013
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Jian-Xin Duan, Hailong Jiao, Jacob Kaizerman
  • Treatment of Cancer Using Hypoxia Activated Prodrugs
    Publication number: 20130202716
    Abstract: Cancer can be treated by administration of a hypoxia-activated prodrug, such as TH-302, alone or in combination with other anticancer agents and/or radiation therapy. In combination therapy, the hypoxia-activated prodrug and another anti-cancer agent or radiation therapy may be administered within the same 24-hour period, and administration of the hypoxia-activated prodrug may be completed prior to beginning administration of the other anticancer agent or radiation therapy.
    Type: Application
    Filed: October 21, 2009
    Publication date: August 8, 2013
    Inventors: Stewart Kroll, Mark Matteucci, Charles P. Hart, Jian-Xin Duan, Karen Curd
  • Hypoxia activated drugs of nitrogen mustard alkylators
    Patent number: 8309554
    Abstract: Hypoxia activated drug compounds having a structure of formula (I) are useful in the treatment of cancer and other hyperproliferative diseases.
    Type: Grant
    Filed: May 14, 2009
    Date of Patent: November 13, 2012
    Assignee: Threshold Pharmaceuticals
    Inventors: Jason Lewis, Mark Matteucci, Tao Chen, Hailong Jiao
  • Compositions and methods for treating cancer
    Patent number: 8299088
    Abstract: Hypoxia-activated prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
    Type: Grant
    Filed: June 12, 2009
    Date of Patent: October 30, 2012
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Photon Rao, Jian-Xin Duan
  • CAMPTOTHECIN DERIVATIVES
    Publication number: 20120165522
    Abstract: Various 14-Nitro, 14-amino, and 14-substituted amino camptothecin derivatives are useful in the treatment of cancer and other hyperproliferative diseases. Various 14-nitro camptothecin derivatives are conveniently prepared by reacting a camptothecin derivative with fuming nitric acid, optionally employing acetic anhydride as a solvent.
    Type: Application
    Filed: June 16, 2010
    Publication date: June 28, 2012
    Inventors: Xiaohong Cai, Jian-Xin Duan, Mark Matteucci, Yeyu Cao, Hailong Jiao
  • Phosphoramidate Alkylator Prodrugs
    Publication number: 20110251159
    Abstract: Phosphoramidate alkylator prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
    Type: Application
    Filed: June 17, 2011
    Publication date: October 13, 2011
    Applicant: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Jian-Xin Duan, Hailong Jiao, Jacob Kaizerman
  • Phosphoramidate alkylator prodrugs
    Patent number: 8003625
    Abstract: Phosphoramidate alkylator prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
    Type: Grant
    Filed: June 29, 2006
    Date of Patent: August 23, 2011
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Jian-Xin Duan, Hailong Jiao, Jacob Kaizerman
  • Hypoxia Activated Drugs Of Nitrogen Mustard Alkylators
    Publication number: 20110190310
    Abstract: Hypoxia activated drug compounds having a structure of formula (I) are useful in the treatment of cancer and other hyperproliferative diseases.
    Type: Application
    Filed: May 14, 2009
    Publication date: August 4, 2011
    Inventors: Jason Lewis, Mark Matteucci, Tao Chen, Hailong Jiao
  • PHOSPHORAMIDATE ALKYLATOR PRODRUGS FOR THE TREATMENT OF CANCER
    Publication number: 20100183742
    Abstract: Compositions containing, and, methods administering, TH302, are useful in treatment of cancer and other hyper-proliferative diseases.
    Type: Application
    Filed: December 21, 2007
    Publication date: July 22, 2010
    Applicant: Threshold Pharmaceuticals, Inc
    Inventors: Steve Ammons, Jian-Xin Duan, Donald Jung, Mark Matteucci
  • PHOSPHORAMIDATE ALKYLATOR PRODRUGS
    Publication number: 20100137254
    Abstract: Phosphoramidate alkylator prodrugs can be used to treat cancer when administered along or in combination with one or more anti-neoplastic agents.
    Type: Application
    Filed: June 29, 2006
    Publication date: June 3, 2010
    Inventors: Mark Matteucci, Jian-Xin Duan, Hailong Jiao
  • Compositions and Methods for Treating Cancer
    Publication number: 20090312276
    Abstract: Hypoxia-activated prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
    Type: Application
    Filed: June 12, 2009
    Publication date: December 17, 2009
    Inventors: Mark Matteucci, Photon Rao, Jian-Xin Duan
  • Compositions and methods for treating cancer
    Patent number: 7550496
    Abstract: Hypoxia-activated prodrugs can be used to treat cancer when administered alone or in combination with one or more anti-neoplastic agents.
    Type: Grant
    Filed: March 29, 2004
    Date of Patent: June 23, 2009
    Assignee: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Photon Rao, Jian-Xin Duan
  • Tubulin Binding Anti Cancer Agents And Prodrugs Thereof
    Publication number: 20090042820
    Abstract: Novel tubulin binding compounds and hypoxia activated prodrugs of novel and known tubulin binding compounds useful for treating cancer and other hyperproliferative diseases are disclosed.
    Type: Application
    Filed: November 17, 2005
    Publication date: February 12, 2009
    Applicant: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Jian-Xin Duan, Xiaohong Cai
  • Topoisomerase Inhibitors and Prodrugs
    Publication number: 20080214576
    Abstract: Compositions and methods for treating cancer and other hyperproliferatice disease conditions with topoisomerase inhibitors and their prodrugs are disclosed.
    Type: Application
    Filed: November 27, 2005
    Publication date: September 4, 2008
    Applicant: Threshold Pharmaceuticals, Inc.
    Inventors: Mark Matteucci, Jian-Xin Duan, Photon Rao